Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis

Mult Scler. 2020 Jan;26(1):123-126. doi: 10.1177/1352458518813110. Epub 2019 Mar 18.

Authors

Cinzia Valeria Russo¹, Francesco Saccà¹, Mariano Paternoster², Antonio Riccardo Buonomo³, Ivan Gentile³, Riccardo Scotto³, Vincenzo Brescia Morra¹, Gelsomina Mansueto²

Affiliations

¹ Department of Neurological Sciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy.
² Pathology Section, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
³ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 30882274
DOI: 10.1177/1352458518813110

No abstract available

Keywords: Multiple sclerosis; alemtuzumab; aspergillosis; infection.

Publication types

Case Reports

MeSH terms

Adult
Alemtuzumab / adverse effects*
Female
Humans
Immunologic Factors / adverse effects*
Invasive Pulmonary Aspergillosis / chemically induced*
Invasive Pulmonary Aspergillosis / diagnosis*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

Immunologic Factors
Alemtuzumab